Federal Circuit Reverses PTAB Decision in Bausch & Lomb Patent Case on Lumify Eye Drops

The United States Court of Appeals for the Federal Circuit has determined that the Patent Trial and Appeal Board (PTAB) incorrectly invalidated all claims of a patent licensed by Bausch & Lomb for its Lumify eye drops. The ruling on Monday targeted the PTAB’s claim construction methodology, which the court found erroneous in its decision to favor Slayback Pharma, a generics manufacturer. This decision underscores the complexities involved in patent litigation, particularly in the pharmaceutical industry, where claim construction can significantly alter the outcomes of patent disputes. For further details, access the original article on Law360.